Evidence map›Paper›PMID 24951642›Full record

ArticleBrain : a journal of neurology2014

Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

Rafael González-Redondo, David García-García, Pedro Clavero, Carmen Gasca-Salas, Reyes García-Eulate, José L Zubieta, Javier Arbizu, José A Obeso, María C Rodríguez-Oroz

Abstract readComparative Study
In one paragraph

Article in Brain : a journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rafael González-Redondo1 Department of Neurology, Clinica Universidad de Navarra Medical School, Pamplona, Spain2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
David García-García2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Pedro Clavero1 Department of Neurology, Clinica Universidad de Navarra Medical School, Pamplona, Spain2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Carmen Gasca-Salas1 Department of Neurology, Clinica Universidad de Navarra Medical School, Pamplona, Spain2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Reyes García-Eulate4 Department of Radiology, Clinica Universidad de Navarra Medical School, Pamplona, Spain.
José L Zubieta4 Department of Radiology, Clinica Universidad de Navarra Medical School, Pamplona, Spain.
Javier Arbizu5 Department of Nuclear Medicine, Clinica Universidad de Navarra Medical School, Pamplona, Spain.
José A Obeso1 Department of Neurology, Clinica Universidad de Navarra Medical School, Pamplona, Spain2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
María C Rodríguez-Oroz1 Department of Neurology, Clinica Universidad de Navarra Medical School, Pamplona, Spain2 Neuroscience Centre, CIMA, Pamplona, Spain3 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain maria.rodriguezoroz@biodonostia.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathophysiological process underlying cognitive decline in Parkinson's disease is not well understood. Cerebral atrophy and hypometabolism have been described in patients with Parkinson's disease and dementia or mild cognitive impairment with respect to control subjects. However, the exact relationships between atrophy and hypometabolism are still unclear. To determine the extension and topographical distribution of hypometabolism and atrophy in the different cognitive states of Parkinson's disease, we examined 46 patients with Parkinson's disease (19 female, 27 male; 71.7 ± 5.9 years old; 14.6 ± 4.2 years of disease evolution; modified Hoehn and Yahr mean stage 3.1 ± 0.7). Cognitive status was diagnosed as normal in 14 patients, as mild cognitive impairment in 17 and as dementia in 15 patients. Nineteen normal subjects (eight female, 11 male; 68.1 ± 3.2 years old) were included as controls. (18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging scans were obtained, co-registered, corrected for partial volume effect and spatially normalized to the Montreal Neurological Institute space in each subject. Smoothing was applied to the positron emission tomography and magnetic resonance imaging scans to equalize their effective smoothness and resolution (10 mm and 12 mm full-width at half-maximum and Gaussian kernel, respectively). Z-score maps for atrophy and for hypometabolism were obtained by comparing individual images to the data set of control subjects. For each group of patients, a paired Student's t-test was performed to statistically compare the two Z-map modalities (P < 0.05 false discovery rate corrected) using the direct voxel-based comparison technique. In patients with mild cognitive impairment, hypometabolism exceeded atrophy in the angular gyrus, occipital, orbital and anterior frontal lobes. In patients with dementia, the hypometabolic areas observed in the group with mild cognitive impairment were replaced by areas of atrophy, which were surrounded by extensive zones of hypometabolism. Areas where atrophy was more extended than hypometabolism were found in the precentral and supplementary motor areas in both patients with mild cognitive impairment and with dementia, and in the hippocampus and temporal lobe in patients with dementia. These findings suggest that there is a gradient of severity in cortical changes associated with the development of cognitive impairment in Parkinson's disease in which hypometabolism and atrophy represent consecutive stages of the same process in most of the cortical regions affected.

Indexed as

Cerebral CortexCognitive DysfunctionDementiaParkinson DiseaseAgedAged, 80 and overAtrophyCross-Sectional StudiesFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMaleNeuroimagingPositron-Emission TomographyRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsdementiaFDG-PETmild cognitive impairmentMRIParkinson’s disease

Identifiers

PMID24951642
PMCPMC4610189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.